Treatment of Cholinergic Urticaria

First-Line Treatment: High-Dose Antihistamines

The American College of Allergy, Asthma, and Immunology recommends starting with a second-generation non-sedating H1 antihistamine at standard dose, and if symptoms persist after 2-4 weeks, increase up to 4 times the standard dose before considering other therapies 1, 2
Second-generation H1 antihistamines are the definitive first-line treatment for cholinergic urticaria, with preferred agents including loratadine and mizolastine 1, 2
Offer at least two different non-sedating antihistamines to each patient, as individual responses and tolerance vary significantly between agents 1, 2

For cholinergic urticaria unresponsive to high-dose antihistamines, add omalizumab 300 mg subcutaneously every 4 weeks, based on robust double-blind placebo-controlled studies demonstrating efficacy in chronic spontaneous urticaria 1, 2, 3
Allow up to 6 months for patients to respond before considering treatment failure 1, 2
If insufficient response at standard dosing, increase to 600 mg every 2 weeks as the maximum recommended dose 1, 2

For patients who do not respond to high-dose antihistamines and omalizumab within 6 months, add cyclosporine at 4-5 mg/kg body weight daily, with treatment duration of 16 weeks rather than 8 weeks to reduce therapeutic failures 1, 2, 4
Monitor blood pressure and renal function every 6 weeks due to potential nephrotoxicity and hypertension 1, 2

Restrict oral corticosteroids to short courses of 3-10 days for severe acute exacerbations only, as they should never be used chronically due to cumulative toxicity that outweighs any benefit 1, 2

Identify and minimize aggravating factors, including overheating, stress, alcohol, aspirin and NSAIDs, and codeine 1, 2
Cooling antipruritic lotions, such as calamine or 1% menthol in aqueous cream, can provide symptomatic relief 1

In renal impairment, avoid acrivastine in moderate renal impairment, and halve the dose of cetirizine, levocetirizine, and hydroxyzine in moderate renal impairment 2, 4
In hepatic impairment, avoid mizolastine in significant hepatic impairment, and avoid hydroxyzine in severe liver disease 2, 4
In pregnancy, avoid antihistamines if possible, especially during the first trimester, and if necessary, choose chlorphenamine due to its long safety record 2, 4